Litigation Details for Juno Therapeutics, Inc. v. Kite Pharma, Inc. (C.D. Cal. 2017)

Juno Therapeutics, Inc. v. Kite Pharma, Inc. (C.D. Cal. 2017)

Docket		Date Filed	2017-10-18
Court	District Court, C.D. California	Date Terminated	2020-04-08
Cause	35:271 Patent Infringement	Assigned To	George H. Wu
Jury Demand	Both	Referred To	Karen L. Stevenson
Parties	JUNO THERAPEUTICS, INC.
Patents	10,960,009; 11,975,017; 12,151,024; 8,722,021
Attorneys	Alan J Heinrich
Firms	Milbank LLP
Link to Docket	External link to docket

Details for Juno Therapeutics, Inc. v. Kite Pharma, Inc. (C.D. Cal. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-10-18				External link to document

Juno Therapeutics v. Kite Pharma: Litigation Summary, Patent Analysis, and Case Status

Last updated: August 2, 2026

Juno Therapeutics, Inc. v. Kite Pharma, Inc., No. 2:17-cv-07639, was a major CAR-T patent dispute involving Juno’s U.S. Patent No. 7,446,190 and Kite’s Yescarta therapy. A Central District of California jury found Kite liable and awarded approximately $752 million. The district court later enhanced the award to roughly $1.2 billion and imposed an ongoing royalty. The Federal Circuit reversed, holding that the asserted claims lacked adequate written description under 35 U.S.C. § 112. The Supreme Court declined review, leaving the patent invalid and eliminating the damages award and royalty obligation. [1][2]

What patents were asserted in Juno Therapeutics v. Kite Pharma?

The case centered on U.S. Patent No. 7,446,190, titled “Nucleic Acids Encoding Chimeric T Cell Receptors,” assigned to Juno Therapeutics and licensed from Memorial Sloan Kettering Cancer Center-related interests. The patent covered chimeric antigen receptors, or CARs, used to genetically modify T cells so they recognize and attack cancer cells.

Patent at issue

Patent	Technology	Patent owner or exclusive licensee	Litigation result
U.S. Patent No. 7,446,190	Chimeric T-cell receptors and nucleic acids encoding them	Juno Therapeutics and affiliated licensors	Invalidated for lack of written description

The asserted claims required a CAR containing:

• A binding element, such as an antibody fragment;
• A transmembrane domain;
• An intracellular signaling domain derived from the CD3-zeta chain; and
• A structure capable of activating T cells after antigen binding.

The commercial product at issue was Kite’s axicabtagene ciloleucel, marketed as Yescarta. Yescarta is an autologous anti-CD19 CAR-T therapy approved by the FDA for certain B-cell malignancies. [3]

What was the case timeline in Juno v. Kite?

Date	Event
December 8, 1995	Earliest priority date associated with the patent family
November 4, 2008	U.S. Patent No. 7,446,190 issued
October 18, 2017	FDA approved Yescarta
December 4, 2017	Juno filed the patent infringement complaint in the Central District of California
November-December 2019	Jury trial took place
December 2019	Jury found infringement and awarded approximately $752 million
January 2020	District court enhanced damages to approximately $1.2 billion and imposed an ongoing royalty
August 26, 2021	Federal Circuit reversed, holding the asserted claims invalid for lack of written description
November 2022	Supreme Court denied certiorari
2022 onward	No enforceable damages award or ongoing royalty remained

The docket number is 2:17-cv-07639 in the U.S. District Court for the Central District of California. The case was assigned to Judge Dale S. Fischer.

Why did Juno sue Kite over Yescarta?

Juno alleged that Yescarta’s anti-CD19 CAR construct practiced claims of the ’190 patent. Kite developed Yescarta using a CAR architecture containing an antibody-derived binding domain, a transmembrane segment, and a CD3-zeta signaling component.

Juno asserted:

1. Direct infringement by Kite’s manufacture and sale of Yescarta;
2. Indirect infringement based on Kite’s activities relating to use of the product; and
3. Willful infringement, which supported the request for enhanced damages.

The dispute had substantial commercial significance because Yescarta was one of the first approved CAR-T therapies and was expected to generate significant revenue for Kite and its acquirer, Gilead Sciences.

What did the jury decide in the Juno patent trial?

The jury found that Kite infringed the asserted claims and that the patent was not invalid on the grounds presented at trial. It awarded Juno approximately $752 million in damages.

The verdict included compensation based on a royalty theory. Public reporting characterized the award as approximately $585 million in compensatory damages plus additional amounts associated with the jury’s infringement findings and royalty calculation. The district court later entered a larger judgment after finding the infringement willful.

The district court determined that Kite’s infringement was sufficiently culpable to justify enhanced damages under 35 U.S.C. § 284. The court increased the award to approximately $1.2 billion and ordered an ongoing royalty of approximately 27.6% on future Yescarta sales for the remaining patent term. [4]

Why did the Federal Circuit invalidate Juno’s CAR-T patent?

The Federal Circuit reversed because the patent specification did not demonstrate possession of the full scope of the asserted genus claims as of the filing date.

Written description issue

The patent claims covered a broad class of CARs using functional language for the binding element. The specification disclosed particular antibody fragments and examples, but the claims reached a much broader range of possible binding elements.

The Federal Circuit applied the written description standard under Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co. The issue was not whether a skilled artisan could make or use the claimed CARs. The issue was whether the patent specification showed that the inventors possessed the full claimed genus when they filed the application. [5]

The court concluded that the specification did not identify a representative number of species or provide sufficient common structural features across the claimed genus. It described the claimed scope as broad relative to the limited examples and teachings in the specification.

Federal Circuit holding

The Federal Circuit held that the asserted claims were invalid under 35 U.S.C. § 112(a) for lack of written description. The court therefore vacated:

• The infringement judgment;
• The approximately $752 million jury award;
• The enhanced damages judgment;
• The ongoing royalty; and
• Related post-trial orders.

The court did not need to resolve all remaining infringement and validity questions because the written description defect was dispositive. [1]

What was the Supreme Court status of Juno v. Kite?

Juno petitioned the U.S. Supreme Court for review. The petition challenged the Federal Circuit’s application of the written description requirement to genus claims covering CAR-T constructs.

The Supreme Court denied certiorari in 2022. The denial left the Federal Circuit’s decision intact. The ’190 patent could not support the damages award or continuing royalty imposed by the district court.

The Supreme Court’s denial did not create a new merits holding. It ended the appellate path in the case and preserved the Federal Circuit’s written description ruling as the controlling disposition for the parties.

What was the Orange Book and FDA status of the dispute?

The case was not an Orange Book patent case.

Yescarta is a biologic licensed under a biologics license application, or BLA. It is not a conventional small-molecule drug approved under an NDA and listed in the FDA Orange Book. As a result:

• There was no Orange Book listing for the ’190 patent;
• Kite did not face an abbreviated new drug application, or ANDA, Paragraph IV certification;
• The dispute did not involve Hatch-Waxman litigation;
• The relevant regulatory pathway was the BLA and, for future competitors, the Biologics Price Competition and Innovation Act framework.

The litigation was a conventional patent infringement action against the product manufacturer. It did not involve a biosimilar applicant challenging a reference-product patent through the BPCIA patent-exchange process.

Was Yescarta exposed to biosimilar competition?

The patent case created biologic patent risk, but it was not itself a biosimilar case. A biosimilar entrant would need to address FDA regulatory requirements and applicable patent rights independently of the Juno judgment.

The invalidation of the ’190 patent reduced one potential barrier to competing CAR-T development. It did not eliminate other patent rights covering:

• CAR constructs;
• Antibody-binding domains;
• Cell-processing methods;
• Viral vectors;
• T-cell activation and expansion;
• Manufacturing controls;
• Formulation and cryopreservation; and
• Clinical use of CAR-T products.

How strong was Juno’s patent estate?

The ’190 patent was commercially important but legally vulnerable because of the breadth of its genus claims relative to the specification.

Strengths

• It addressed core CAR-T architecture.
• It had an early priority position.
• It covered functional CAR elements used in a leading commercial therapy.
• It was asserted against a high-value product with substantial sales potential.
• A jury initially accepted Juno’s infringement and validity theories.

Weaknesses

• The asserted claims covered a broad genus of binding elements.
• The specification provided limited representative examples.
• The claims relied heavily on functional descriptions rather than a sufficiently developed structural roadmap.
• The Federal Circuit treated the disclosure as inadequate under the written description requirement.
• The patent’s commercial relevance did not cure its disclosure defect.

The case illustrates the distinction between enablement and written description. A patent may teach a skilled artisan how to construct or test members of a genus while still failing to demonstrate possession of the entire claimed genus.

What formulation and method-of-use patents were involved?

The reported judgment focused on the ’190 patent and the CAR structure. The case did not produce a final damages judgment based on a separate Yescarta formulation patent, manufacturing patent, or method-of-use patent.

The ’190 patent was primarily a platform and construct patent. It did not operate like a conventional pharmaceutical patent directed to:

• A tablet or injectable formulation;
• A crystalline polymorph;
• A dosing regimen;
• A treatment duration;
• A combination therapy; or
• A manufacturing process for commercial-scale production.

The decision therefore does not establish that all Yescarta-related intellectual property was invalid. It invalidated the asserted claims of the ’190 patent for written description.

Did Juno and Kite settle the litigation?

The public disposition was a judgment followed by appellate reversal, not a reported settlement agreement.

The district court’s enhanced judgment and ongoing royalty were overturned by the Federal Circuit. The Supreme Court’s denial of review left the reversal in place. No enforceable royalty stream under the ’190 patent remained after the appellate decision.

The case should therefore be distinguished from pharmaceutical patent settlements in which a generic or biosimilar receives a delayed entry date. Juno v. Kite did not produce a public authorized-entry settlement, license-based launch date, or reverse-payment agreement.

Which companies were involved in the dispute?

Company	Role
Juno Therapeutics, Inc.	Plaintiff and patent holder or exclusive licensee
Kite Pharma, Inc.	Defendant and Yescarta developer
Gilead Sciences, Inc.	Parent company of Kite after its 2017 acquisition
Memorial Sloan Kettering-related entities	Source of technology and licensing interests associated with the patent

Gilead acquired Kite in October 2017, shortly after Yescarta received FDA approval and before the complaint was filed. The acquisition placed the litigation risk within Gilead’s cell-therapy business.

What was the revenue exposure from the Juno patent case?

The potential exposure was large because the case targeted Yescarta sales rather than a pre-commercial development program.

The district court’s approximately 27.6% ongoing royalty would have materially affected Yescarta economics during the remaining patent term. The approximately $1.2 billion enhanced judgment also represented a significant one-time liability relative to the product’s early commercial revenue.

The Federal Circuit reversal removed that exposure. Gilead retained the ability to commercialize Yescarta without paying the court-ordered royalty under the invalidated patent.

Yescarta later became a major Gilead cell-therapy product. Its continued sales after the Federal Circuit decision demonstrate the commercial importance of the ruling, although post-decision sales cannot be treated as damages under the ’190 patent.

What generic launch risks existed for Yescarta?

A conventional generic launch scenario did not apply because Yescarta is a biologic.

The relevant competitive risks were:

• Biosimilar or interchangeable biologic entry;
• Competing autologous CAR-T products;
• Allogeneic CAR-T platforms;
• Other CD19-directed therapies;
• Manufacturing capacity and treatment-center access;
• Clinical differentiation in lymphoma and leukemia indications; and
• Separate patent estates covering competing CAR designs.

The invalidation of the ’190 patent reduced platform-level risk for Yescarta but did not create an immediate biosimilar launch pathway. A biosimilar developer would still need to obtain FDA approval and address other patent and regulatory barriers.

How does Juno v. Kite compare with other CAR-T patent disputes?

Juno v. Kite is distinct from disputes focused on licensing scope, patent ownership, or manufacturing know-how.

Issue	Juno v. Kite
Core technology	CAR construct and signaling architecture
Primary legal issue	Written description under § 112
Commercial product	Yescarta
Regulatory pathway	BLA biologic
Orange Book	Not applicable
Paragraph IV	Not applicable
Trial result	Juno prevailed before jury
Final appellate result	Kite prevailed on invalidity
Royalty outcome	District court royalty vacated
Biosimilar settlement	None publicly reported

The decision is particularly relevant to CAR-T patent drafting. Broad genus claims should be supported by representative species, common structural features, or a sufficiently detailed description showing possession across the claimed scope.

What is the final litigation status of Juno v. Kite?

The final substantive result favored Kite.

The Federal Circuit’s 2021 decision invalidated the asserted ’190 patent claims for lack of written description and vacated the damages and royalty orders. The Supreme Court denied review in 2022. The case therefore does not leave a surviving judgment requiring Kite or Gilead to pay Juno for Yescarta sales.

The practical legal effect was:

1. No enforceable $752 million jury award;
2. No enforceable approximately $1.2 billion enhanced judgment;
3. No continuing 27.6% royalty;
4. No final infringement liability based on the asserted claims; and
5. No public settlement-based restriction on Yescarta commercialization.

Key Takeaways

• Juno sued Kite over Yescarta under U.S. Patent No. 7,446,190.
• The jury initially found infringement and awarded approximately $752 million.
• The district court increased the judgment to roughly $1.2 billion and imposed an ongoing royalty of approximately 27.6%.
• The Federal Circuit reversed in August 2021.
• The asserted claims were held invalid for lack of written description under 35 U.S.C. § 112(a).
• The Supreme Court denied review in 2022.
• The damages award and ongoing royalty were vacated.
• The case did not involve an Orange Book listing, Paragraph IV certification, or biosimilar settlement.
• The ruling reduced one major patent barrier for Yescarta but did not eliminate other CAR-T manufacturing, formulation, platform, or method-of-use patents.
• The case remains a leading written-description decision for broad genus claims in cell and gene therapy patents.

FAQs About Juno Therapeutics v. Kite Pharma

What was the patent number in Juno Therapeutics v. Kite Pharma?

The principal patent was U.S. Patent No. 7,446,190, covering nucleic acids and chimeric T-cell receptor constructs.

How much did Juno originally win against Kite?

The jury awarded approximately $752 million. The district court later increased the judgment to approximately $1.2 billion before the Federal Circuit vacated it.

Did Kite have to pay Juno a royalty on Yescarta sales?

No. The district court ordered an ongoing royalty of approximately 27.6%, but the Federal Circuit reversed the judgment and vacated the royalty.

Why was the Juno CAR-T patent invalidated?

The Federal Circuit held that the patent specification did not adequately demonstrate possession of the full scope of the broad genus claims at the filing date.

Did the case block Yescarta sales?

No. The final appellate result removed the damages and royalty liability, and the case did not impose a continuing injunction against Yescarta sales.

Was Juno v. Kite a biosimilar or Paragraph IV case?

No. Yescarta is a biologic regulated under a BLA. The dispute was a direct patent infringement action, not an Orange Book or Hatch-Waxman Paragraph IV case.

References

1. U.S. Court of Appeals for the Federal Circuit. (2021). Juno Therapeutics, Inc. v. Kite Pharma, Inc., 10 F.4th 1330.
2. Supreme Court of the United States. (2022). Juno Therapeutics, Inc. v. Kite Pharma, Inc., No. 21-1566, certiorari denied.
3. U.S. Food and Drug Administration. (2017). FDA approves CAR-T cell therapy to treat certain blood cancers.
4. U.S. District Court for the Central District of California. (2017-2021). Juno Therapeutics, Inc. v. Kite Pharma, Inc., No. 2:17-cv-07639.
5. U.S. Court of Appeals for the Federal Circuit. (2010). Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., 598 F.3d 1336.